LHDX.Q Stock Overview
Lucira Health, Inc. is in the process of liquidation. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lucira Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.000001 |
| Beta | 2.39 |
| 1 Month Change | -50.00% |
| 3 Month Change | -99.44% |
| 1 Year Change | -99.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Lucira Health reports early data for point of care chlamydia and gonorrhea assays
Sep 29Lucira COVID & Flu test gets emergency use authorization from Health Canada
Aug 11Lucira Health Sees Strong Revenue Growth But Needs More Cash
Mar 10Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher
Nov 25
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?
Jun 29Lucira Health appoints medtech veteran Kevin Collins as CRO
May 28Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit
Apr 26Shareholder Returns
| LHDX.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -2.4% |
| 1Y | -100.0% | 10.0% | 23.4% |
Return vs Industry: LHDX.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: LHDX.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| LHDX.Q volatility | |
|---|---|
| LHDX.Q Average Weekly Movement | 2,860.0% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LHDX.Q's share price has been volatile over the past 3 months.
Volatility Over Time: LHDX.Q's weekly volatility has increased from 1417% to 2860% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 221 | n/a | www.lucirahealth.com |
Lucira Health, Inc. is in the process of liquidation. Previously, the company engaged in the development and commercialization of infectious disease test kits. It developed a testing platform that produces molecular testing services.
Lucira Health, Inc. Fundamentals Summary
| LHDX.Q fundamental statistics | |
|---|---|
| Market cap | US$4.18k |
| Earnings (TTM) | -US$143.28m |
| Revenue (TTM) | US$212.13m |
0.0x
P/S Ratio0.0x
P/E RatioIs LHDX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LHDX.Q income statement (TTM) | |
|---|---|
| Revenue | US$212.13m |
| Cost of Revenue | US$251.34m |
| Gross Profit | -US$39.20m |
| Other Expenses | US$104.07m |
| Earnings | -US$143.28m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.43 |
| Gross Margin | -18.48% |
| Net Profit Margin | -67.54% |
| Debt/Equity Ratio | 48.3% |
How did LHDX.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 12:34 |
| End of Day Share Price | 2023/10/04 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lucira Health, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| David Sherman | LifeSci Capital, LLC |
| Brian Weinstein | William Blair & Company L.L.C. |